JP2004532849A

JP2004532849A - 中枢神経系へのポリヌクレオチド薬剤の送達

中枢神経系へのポリヌクレオチド薬剤の送達 Download PDF

Info

Publication number: JP2004532849A
Authority: JP; Japan
Prior art keywords: polynucleotide; agent; antisense; tissue; olfactory
Prior art date: 2001-04-20
Legal status : Pending

Application number

JP2002583620A

Other languages

English (en)

Japanese (ja)

Other versions

JP2004532849A5 (enExample

Inventor

クリストフレインハード，

ウィリアムエイチ．ツーフレイ，

Original Assignee

カイロンコーポレイション

Priority date

2001-04-20

Filing date

2002-04-19

Publication date

2004-10-28

2002-04-19 Application filed by カイロンコーポレイション filed Critical カイロンコーポレイション

2004-10-28 Publication of JP2004532849A publication Critical patent/JP2004532849A/ja

2005-12-22 Publication of JP2004532849A5 publication Critical patent/JP2004532849A5/ja

Status Pending legal-status Critical Current

Links

108091033319 polynucleotide Proteins 0.000 title claims abstract description 173
102000040430 polynucleotide Human genes 0.000 title claims abstract description 173
239000002157 polynucleotide Substances 0.000 title claims abstract description 173
239000003814 drug Substances 0.000 title claims description 120
229940079593 drug Drugs 0.000 title claims description 111
210000003169 central nervous system Anatomy 0.000 title claims description 104
238000012384 transportation and delivery Methods 0.000 title description 70
239000003795 chemical substances by application Substances 0.000 claims abstract description 245
238000000034 method Methods 0.000 claims abstract description 152
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 126
108090000623 proteins and genes Proteins 0.000 claims abstract description 92
210000003901 trigeminal nerve Anatomy 0.000 claims abstract description 71
102000004169 proteins and genes Human genes 0.000 claims abstract description 64
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 59
210000003928 nasal cavity Anatomy 0.000 claims abstract description 53
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 36
229920001184 polypeptide Polymers 0.000 claims abstract description 27
241000124008 Mammalia Species 0.000 claims abstract description 18
210000000118 neural pathway Anatomy 0.000 claims abstract description 14
230000010004 neural pathway Effects 0.000 claims abstract description 14
210000001519 tissue Anatomy 0.000 claims description 132
230000000692 anti-sense effect Effects 0.000 claims description 127
239000000203 mixture Substances 0.000 claims description 87
108020004999 messenger RNA Proteins 0.000 claims description 77
239000002773 nucleotide Substances 0.000 claims description 70
125000003729 nucleotide group Chemical group 0.000 claims description 70
210000004027 cell Anatomy 0.000 claims description 62
108091093037 Peptide nucleic acid Proteins 0.000 claims description 52
210000000278 spinal cord Anatomy 0.000 claims description 43
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
230000000295 complement effect Effects 0.000 claims description 35
210000002751 lymph Anatomy 0.000 claims description 26
238000013519 translation Methods 0.000 claims description 22
208000035475 disorder Diseases 0.000 claims description 20
230000037361 pathway Effects 0.000 claims description 19
230000001225 therapeutic effect Effects 0.000 claims description 19
208000015114 central nervous system disease Diseases 0.000 claims description 18
210000000956 olfactory bulb Anatomy 0.000 claims description 17
239000013612 plasmid Substances 0.000 claims description 15
102000005962 receptors Human genes 0.000 claims description 13
108020003175 receptors Proteins 0.000 claims description 13
210000001638 cerebellum Anatomy 0.000 claims description 11
210000000795 conjunctiva Anatomy 0.000 claims description 11
102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 10
108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 10
210000000133 brain stem Anatomy 0.000 claims description 10
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 9
230000007170 pathology Effects 0.000 claims description 9
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 8
230000001054 cortical effect Effects 0.000 claims description 8
208000015122 neurodegenerative disease Diseases 0.000 claims description 8
230000000926 neurological effect Effects 0.000 claims description 8
208000024827 Alzheimer disease Diseases 0.000 claims description 7
230000002739 subcortical effect Effects 0.000 claims description 7
210000001185 bone marrow Anatomy 0.000 claims description 6
230000002500 effect on skin Effects 0.000 claims description 6
210000001259 mesencephalon Anatomy 0.000 claims description 6
201000009906 Meningitis Diseases 0.000 claims description 5
208000012902 Nervous system disease Diseases 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
208000019022 Mood disease Diseases 0.000 claims description 4
208000024777 Prion disease Diseases 0.000 claims description 4
230000001681 protective effect Effects 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 3
102000004584 Somatomedin Receptors Human genes 0.000 claims description 3
108010017622 Somatomedin Receptors Proteins 0.000 claims description 3
208000029028 brain injury Diseases 0.000 claims description 3
206010015037 epilepsy Diseases 0.000 claims description 3
208000020016 psychiatric disease Diseases 0.000 claims description 3
206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
206010012289 Dementia Diseases 0.000 claims description 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 2
208000005264 motor neuron disease Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 claims description 2
208000020431 spinal cord injury Diseases 0.000 claims description 2
102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
102000003840 Opioid Receptors Human genes 0.000 claims 2
108090000137 Opioid Receptors Proteins 0.000 claims 2
208000017194 Affective disease Diseases 0.000 claims 1
208000003174 Brain Neoplasms Diseases 0.000 claims 1
208000031886 HIV Infections Diseases 0.000 claims 1
208000037357 HIV infectious disease Diseases 0.000 claims 1
206010028289 Muscle atrophy Diseases 0.000 claims 1
208000006011 Stroke Diseases 0.000 claims 1
206010013663 drug dependence Diseases 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
201000010901 lateral sclerosis Diseases 0.000 claims 1
230000020763 muscle atrophy Effects 0.000 claims 1
201000000585 muscular atrophy Diseases 0.000 claims 1
206010062261 spinal cord neoplasm Diseases 0.000 claims 1
208000011117 substance-related disease Diseases 0.000 claims 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 51
230000014509 gene expression Effects 0.000 abstract description 31
238000002360 preparation method Methods 0.000 abstract description 11
230000004071 biological effect Effects 0.000 abstract description 6
239000000074 antisense oligonucleotide Substances 0.000 description 61
238000012230 antisense oligonucleotides Methods 0.000 description 61
210000004556 brain Anatomy 0.000 description 48
150000007523 nucleic acids Chemical class 0.000 description 41
235000018102 proteins Nutrition 0.000 description 41
210000005036 nerve Anatomy 0.000 description 39
238000001727 in vivo Methods 0.000 description 34
108020004414 DNA Proteins 0.000 description 30
102000039446 nucleic acids Human genes 0.000 description 30
108020004707 nucleic acids Proteins 0.000 description 30
210000000196 olfactory nerve Anatomy 0.000 description 30
210000000981 epithelium Anatomy 0.000 description 28
108091032973 (ribonucleotides)n+m Proteins 0.000 description 27
108020000948 Antisense Oligonucleotides Proteins 0.000 description 25
238000002716 delivery method Methods 0.000 description 24
230000032258 transport Effects 0.000 description 24
210000002569 neuron Anatomy 0.000 description 23
150000003839 salts Chemical class 0.000 description 23
230000008499 blood brain barrier function Effects 0.000 description 22
210000001218 blood-brain barrier Anatomy 0.000 description 22
201000010099 disease Diseases 0.000 description 21
239000000178 monomer Substances 0.000 description 21
210000004877 mucosa Anatomy 0.000 description 21
230000014616 translation Effects 0.000 description 21
108091028043 Nucleic acid sequence Proteins 0.000 description 20
238000009472 formulation Methods 0.000 description 19
206010028980 Neoplasm Diseases 0.000 description 18
241000700159 Rattus Species 0.000 description 18
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 18
230000000694 effects Effects 0.000 description 17
210000000744 eyelid Anatomy 0.000 description 16
210000002850 nasal mucosa Anatomy 0.000 description 16
239000012730 sustained-release form Substances 0.000 description 16
230000002123 temporal effect Effects 0.000 description 16
210000001508 eye Anatomy 0.000 description 15
-1 ribonucleoside triphosphates Chemical class 0.000 description 15
210000004761 scalp Anatomy 0.000 description 15
238000013268 sustained release Methods 0.000 description 15
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 14
239000008194 pharmaceutical composition Substances 0.000 description 14
239000000126 substance Substances 0.000 description 14
210000002105 tongue Anatomy 0.000 description 14
230000027455 binding Effects 0.000 description 13
210000003467 cheek Anatomy 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
210000000214 mouth Anatomy 0.000 description 13
239000002777 nucleoside Substances 0.000 description 13
101710163270 Nuclease Proteins 0.000 description 12
239000003205 fragrance Substances 0.000 description 12
210000004228 maxillary nerve Anatomy 0.000 description 12
230000007246 mechanism Effects 0.000 description 12
230000001404 mediated effect Effects 0.000 description 12
210000004400 mucous membrane Anatomy 0.000 description 12
210000001331 nose Anatomy 0.000 description 12
210000002475 olfactory pathway Anatomy 0.000 description 12
230000002792 vascular Effects 0.000 description 12
210000004204 blood vessel Anatomy 0.000 description 11
239000002502 liposome Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
230000007433 nerve pathway Effects 0.000 description 10
150000004713 phosphodiesters Chemical class 0.000 description 10
108091026890 Coding region Proteins 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
108010031794 IGF Type 1 Receptor Proteins 0.000 description 9
102000038455 IGF Type 1 Receptor Human genes 0.000 description 9
102100034343 Integrase Human genes 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
230000006870 function Effects 0.000 description 9
239000003102 growth factor Substances 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
210000002698 mandibular nerve Anatomy 0.000 description 9
239000013598 vector Substances 0.000 description 9
101710203526 Integrase Proteins 0.000 description 8
108091028664 Ribonucleotide Proteins 0.000 description 8
239000000654 additive Substances 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
238000013461 design Methods 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
230000003834 intracellular effect Effects 0.000 description 8
210000004940 nucleus Anatomy 0.000 description 8
210000001706 olfactory mucosa Anatomy 0.000 description 8
239000002336 ribonucleotide Substances 0.000 description 8
230000035807 sensation Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
235000000346 sugar Nutrition 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
238000012546 transfer Methods 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
108091026898 Leader sequence (mRNA) Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
239000000969 carrier Substances 0.000 description 7
239000003184 complementary RNA Substances 0.000 description 7
230000006378 damage Effects 0.000 description 7
239000003937 drug carrier Substances 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
210000004283 incisor Anatomy 0.000 description 7
230000001926 lymphatic effect Effects 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 7
210000000492 nasalseptum Anatomy 0.000 description 7
210000001328 optic nerve Anatomy 0.000 description 7
210000002975 pon Anatomy 0.000 description 7
230000002265 prevention Effects 0.000 description 7
230000010076 replication Effects 0.000 description 7
239000011734 sodium Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
150000001413 amino acids Chemical group 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
239000000306 component Substances 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
208000014674 injury Diseases 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
230000001537 neural effect Effects 0.000 description 6
102000052563 odorant-binding protein Human genes 0.000 description 6
108010000645 odorant-binding protein Proteins 0.000 description 6
229940046166 oligodeoxynucleotide Drugs 0.000 description 6
229960001412 pentobarbital Drugs 0.000 description 6
239000000843 powder Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
239000000725 suspension Substances 0.000 description 6
239000013603 viral vector Substances 0.000 description 6
108020005544 Antisense RNA Proteins 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
230000004570 RNA-binding Effects 0.000 description 5
108091081024 Start codon Proteins 0.000 description 5
108091036066 Three prime untranslated region Proteins 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
210000002808 connective tissue Anatomy 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
210000002451 diencephalon Anatomy 0.000 description 5
238000012377 drug delivery Methods 0.000 description 5
206010014599 encephalitis Diseases 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
210000004561 lacrimal apparatus Anatomy 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 5
239000002858 neurotransmitter agent Substances 0.000 description 5
150000003833 nucleoside derivatives Chemical class 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000008884 pinocytosis Effects 0.000 description 5
210000003370 receptor cell Anatomy 0.000 description 5
125000002652 ribonucleotide group Chemical group 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
241000701161 unidentified adenovirus Species 0.000 description 5
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
241001269524 Dura Species 0.000 description 4
108060002716 Exonuclease Proteins 0.000 description 4
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
108010025020 Nerve Growth Factor Proteins 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
230000003444 anaesthetic effect Effects 0.000 description 4
210000003484 anatomy Anatomy 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
210000003050 axon Anatomy 0.000 description 4
239000000227 bioadhesive Substances 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
230000004700 cellular uptake Effects 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
210000001175 cerebrospinal fluid Anatomy 0.000 description 4
230000001886 ciliary effect Effects 0.000 description 4
230000004087 circulation Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
239000008121 dextrose Substances 0.000 description 4
102000013165 exonuclease Human genes 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
210000004195 gingiva Anatomy 0.000 description 4
229920002674 hyaluronan Polymers 0.000 description 4
229960003160 hyaluronic acid Drugs 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000003993 interaction Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000010534 mechanism of action Effects 0.000 description 4
201000011475 meningoencephalitis Diseases 0.000 description 4
239000003094 microcapsule Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
229940105631 nembutal Drugs 0.000 description 4
210000004498 neuroglial cell Anatomy 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
125000003835 nucleoside group Chemical group 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000000737 periodic effect Effects 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
125000005642 phosphothioate group Chemical group 0.000 description 4
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000001953 sensory effect Effects 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
239000007921 spray Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108020003589 5' Untranslated Regions Proteins 0.000 description 3
206010003571 Astrocytoma Diseases 0.000 description 3
208000014644 Brain disease Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
102000004533 Endonucleases Human genes 0.000 description 3
108010042407 Endonucleases Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010009202 Growth Factor Receptors Proteins 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
102000015336 Nerve Growth Factor Human genes 0.000 description 3
102000012547 Olfactory receptors Human genes 0.000 description 3
108050002069 Olfactory receptors Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
239000004952 Polyamide Substances 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
210000005178 buccal mucosa Anatomy 0.000 description 3
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 3
210000005056 cell body Anatomy 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000007850 degeneration Effects 0.000 description 3
230000012202 endocytosis Effects 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
239000005038 ethylene vinyl acetate Substances 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
102000034356 gene-regulatory proteins Human genes 0.000 description 3
108091006104 gene-regulatory proteins Proteins 0.000 description 3
239000008103 glucose Substances 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
210000001320 hippocampus Anatomy 0.000 description 3
239000000017 hydrogel Substances 0.000 description 3
210000001847 jaw Anatomy 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000000865 liniment Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
210000001365 lymphatic vessel Anatomy 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
210000004086 maxillary sinus Anatomy 0.000 description 3
239000000693 micelle Substances 0.000 description 3
239000004005 microsphere Substances 0.000 description 3
229940053128 nerve growth factor Drugs 0.000 description 3
208000007538 neurilemmoma Diseases 0.000 description 3
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
210000003695 paranasal sinus Anatomy 0.000 description 3
239000000863 peptide conjugate Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
229920002647 polyamide Polymers 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
150000004804 polysaccharides Chemical class 0.000 description 3
230000008569 process Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
239000002342 ribonucleoside Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
241000894007 species Species 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
230000005945 translocation Effects 0.000 description 3
230000001927 transneuronal effect Effects 0.000 description 3
210000003454 tympanic membrane Anatomy 0.000 description 3
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
229920001287 Chondroitin sulfate Polymers 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
241001503776 Cylas Species 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
208000016192 Demyelinating disease Diseases 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000991587 Enterovirus C Species 0.000 description 2
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
235000010254 Jasminum officinale Nutrition 0.000 description 2
240000005385 Jasminum sambac Species 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000016604 Lyme disease Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
208000009905 Neurofibromatoses Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
102000017922 Neurotensin receptor Human genes 0.000 description 2
108060003370 Neurotensin receptor Proteins 0.000 description 2
108091092724 Noncoding DNA Proteins 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000000274 adsorptive effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
230000008335 axon cargo transport Effects 0.000 description 2
210000001142 back Anatomy 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000012503 blood component Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229940105329 carboxymethylcellulose Drugs 0.000 description 2
229960003260 chlorhexidine Drugs 0.000 description 2
229940099352 cholate Drugs 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
229940059329 chondroitin sulfate Drugs 0.000 description 2
QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
229930003836 cresol Natural products 0.000 description 2
102000003675 cytokine receptors Human genes 0.000 description 2
108010057085 cytokine receptors Proteins 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
210000001787 dendrite Anatomy 0.000 description 2
229940009976 deoxycholate Drugs 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
239000005549 deoxyribonucleoside Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000002224 dissection Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
210000000624 ear auricle Anatomy 0.000 description 2
210000005069 ears Anatomy 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000007515 enzymatic degradation Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000003722 extracellular fluid Anatomy 0.000 description 2
210000000256 facial nerve Anatomy 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000000834 fixative Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
210000001061 forehead Anatomy 0.000 description 2
210000005153 frontal cortex Anatomy 0.000 description 2
229960004675 fusidic acid Drugs 0.000 description 2
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 2
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
210000003128 head Anatomy 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000010354 integration Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000002859 lingual nerve Anatomy 0.000 description 2
210000004324 lymphatic system Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
210000004083 nasolacrimal duct Anatomy 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
201000004931 neurofibromatosis Diseases 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000001517 olfactory receptor neuron Anatomy 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
210000003254 palate Anatomy 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
235000019419 proteases Nutrition 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000007441 retrograde transport Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
206010039667 schwannoma Diseases 0.000 description 2
230000008786 sensory perception of smell Effects 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
210000002330 subarachnoid space Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000031998 transcytosis Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
108700026220 vif Genes Proteins 0.000 description 2
210000000216 zygoma Anatomy 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
KTCKNHCDUKONFQ-DJLDLDEBSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(methoxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](COC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 KTCKNHCDUKONFQ-DJLDLDEBSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
HMKKIXGYKWDQSV-SDNWHVSQSA-N 2-Pentyl-3-phenyl-2-propenal Chemical compound CCCCC\C(C=O)=C/C1=CC=CC=C1 HMKKIXGYKWDQSV-SDNWHVSQSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
108020005065 3' Flanking Region Proteins 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
108020005029 5' Flanking Region Proteins 0.000 description 1
108091027075 5S-rRNA precursor Proteins 0.000 description 1
ZMYDAPJHGNEFGQ-UHFFFAOYSA-N 6-(2-fluorophenyl)-5h-[1,3]dioxolo[4,5-g]quinolin-8-one Chemical compound FC1=CC=CC=C1C(NC1=C2)=CC(=O)C1=CC1=C2OCO1 ZMYDAPJHGNEFGQ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
206010002653 Anosmia Diseases 0.000 description 1
108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000004020 Brain Abscess Diseases 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
208000014912 Central Nervous System Infections Diseases 0.000 description 1
206010008027 Cerebellar atrophy Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
101710172562 Cobra venom factor Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000402754 Erythranthe moschata Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
206010017065 Foster-Kennedy Syndrome Diseases 0.000 description 1
208000024412 Friedreich ataxia Diseases 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
102000011392 Galanin receptor Human genes 0.000 description 1
108050001605 Galanin receptor Proteins 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
238000012695 Interfacial polymerization Methods 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
229920000057 Mannan Polymers 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001072332 Monia Species 0.000 description 1
208000026072 Motor neurone disease Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
206010052057 Neuroborreliosis Diseases 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
208000014060 Niemann-Pick disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
208000000609 Pick Disease of the Brain Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
238000010357 RNA editing Methods 0.000 description 1
230000026279 RNA modification Effects 0.000 description 1
108010065868 RNA polymerase SP6 Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
102000008847 Serpin Human genes 0.000 description 1
108050000761 Serpin Proteins 0.000 description 1
208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108091027568 Single-stranded nucleotide Proteins 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
208000029033 Spinal Cord disease Diseases 0.000 description 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
102000005938 Steroid Hydroxylases Human genes 0.000 description 1
108010030741 Steroid Hydroxylases Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000022292 Tay-Sachs disease Diseases 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
238000004026 adhesive bonding Methods 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
GUUHFMWKWLOQMM-NTCAYCPXSA-N alpha-hexylcinnamaldehyde Chemical compound CCCCCC\C(C=O)=C/C1=CC=CC=C1 GUUHFMWKWLOQMM-NTCAYCPXSA-N 0.000 description 1
GUUHFMWKWLOQMM-UHFFFAOYSA-N alpha-n-hexylcinnamic aldehyde Natural products CCCCCCC(C=O)=CC1=CC=CC=C1 GUUHFMWKWLOQMM-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229960004050 aminobenzoic acid Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
235000019558 anosmia Nutrition 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
230000003140 astrocytic effect Effects 0.000 description 1
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
210000001052 bipolar neuron Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004781 brain capillary Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
201000005308 brain ependymoma Diseases 0.000 description 1
230000003925 brain function Effects 0.000 description 1
201000010135 brain oligodendroglioma Diseases 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
210000001043 capillary endothelial cell Anatomy 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
208000025434 cerebellar degeneration Diseases 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
230000000723 chemosensory effect Effects 0.000 description 1
229940045110 chitosan Drugs 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
210000002987 choroid plexus Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
235000000484 citronellol Nutrition 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 1
239000000562 conjugate Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229940013361 cresol Drugs 0.000 description 1
210000003464 cuspid Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
210000000613 ear canal Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000001180 ethmoid sinus Anatomy 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000010435 extracellular transport Effects 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
210000002165 glioblast Anatomy 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
208000010544 human prion disease Diseases 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000012977 invasive surgical procedure Methods 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
229940040145 liniment Drugs 0.000 description 1
230000013190 lipid storage Effects 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
230000016089 mRNA destabilization Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000004373 mandible Anatomy 0.000 description 1
210000003784 masticatory muscle Anatomy 0.000 description 1
230000035800 maturation Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000009061 membrane transport Effects 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
102000051367 mu Opioid Receptors Human genes 0.000 description 1
208000029200 multiple sclerosis variant Diseases 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
230000014524 negative regulation of mRNA processing Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
208000022145 neurocutaneous syndrome Diseases 0.000 description 1
208000002761 neurofibromatosis 2 Diseases 0.000 description 1
208000022032 neurofibromatosis type 2 Diseases 0.000 description 1
208000029974 neurofibrosarcoma Diseases 0.000 description 1
230000003227 neuromodulating effect Effects 0.000 description 1
208000014500 neuronal tumor Diseases 0.000 description 1
208000002040 neurosyphilis Diseases 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
FUBGRVHGQADOJI-UHFFFAOYSA-N octyl 3-methyl-butanoate Chemical compound CCCCCCCCOC(=O)CC(C)C FUBGRVHGQADOJI-UHFFFAOYSA-N 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
210000004273 ophthalmic nerve Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
208000012111 paraneoplastic syndrome Diseases 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
125000004437 phosphorous atom Chemical group 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
239000002745 poly(ortho ester) Substances 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
208000015768 polyposis Diseases 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
210000000063 presynaptic terminal Anatomy 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000004853 protein function Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001814 protein method Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
210000005126 pseudostratified columnar epithelium Anatomy 0.000 description 1
210000002637 putamen Anatomy 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
102000014452 scavenger receptors Human genes 0.000 description 1
108010078070 scavenger receptors Proteins 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000001044 sensory neuron Anatomy 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
210000002265 sensory receptor cell Anatomy 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000002356 single layer Substances 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
229940100515 sorbitan Drugs 0.000 description 1
229940093252 sorbitrate Drugs 0.000 description 1
235000013599 spices Nutrition 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
150000003456 sulfonamides Chemical group 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
150000003457 sulfones Chemical group 0.000 description 1
150000003462 sulfoxides Chemical group 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
108010061506 tau-protein kinase Proteins 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000012360 testing method Methods 0.000 description 1
FJGIHZCEZAZPSP-UHFFFAOYSA-N tetrahedrane Chemical compound C12C3C1C32 FJGIHZCEZAZPSP-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
125000000101 thioether group Chemical group 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
108010062760 transportan Proteins 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000000427 trigeminal ganglion Anatomy 0.000 description 1
210000000836 trigeminal nuclei Anatomy 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
229940117972 triolein Drugs 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
108020001612 μ-opioid receptors Proteins 0.000 description 1